NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

The rumor is that Vertex/CRISPR’s initial application for exa-cel was rejected by the MHRA, and they were required to refile, so it was appropriate in that case to make a second press release that the application was validated and accepted.

This may have prompted the MHRA to become more proactive with applicants after the pre-submission meeting, to ensure that applications are higher quality.